Management of inflammatory bowel disease: Does rifaximin offer any promise?

Chemotherapy

Volumn 51, Issue SUPPL. 1, 2005, Pages 96-102

  Gionchetti, Paolo ^a   Rizzello, Fernando ^a   Morselli, Claudia ^a   Romagnoli, Rossella ^a   Campieri, Massimo ^a  

^a UNIVERSITY OF BOLOGNA   (Italy)

Author keywords

Crohn's disease; Intestinal microflora; Rifaximin; Ulcerative colitis

Indexed keywords

AMOXICILLIN PLUS CLAVULANIC ACID; CIPROFLOXACIN; MESALAZINE; METRONIDAZOLE; PLACEBO; RIFAXIMIN; STEROID; TOBRAMYCIN;

ABDOMINAL CRAMP; ABDOMINAL PAIN; ADD ON THERAPY; ANTIBIOTIC THERAPY; BACTERIUM CULTURE; CROHN DISEASE; DISEASE EXACERBATION; DRUG ABSORPTION; DRUG EFFICACY; DRUG ERUPTION; DRUG EXCRETION; DRUG FORMULATION; DRUG MEGADOSE; DRUG SAFETY; ENTERITIS; FLATULENCE; GASTROINTESTINAL TOXICITY; HUMAN; METEORISM; NAUSEA; PRIORITY JOURNAL; RECURRENT DISEASE; REVIEW; SHORT COURSE THERAPY; SIDE EFFECT; ULCERATIVE COLITIS; VOMITING;

ANTI-BACTERIAL AGENTS; BACTERIA; CIPROFLOXACIN; CLINICAL TRIALS; COLITIS, ULCERATIVE; CROHN DISEASE; HUMANS; INTESTINAL ABSORPTION; INTESTINES; METRONIDAZOLE; RIFAMYCINS;

EID: 18644368241     PISSN: 00093157     EISSN: None     Source Type: Journal    
DOI: 10.1159/000081995     Document Type: Review

References (52)

1. Sartor RB: Enteric microflora in IBD: Pathogens or commensal? Inflamm Bowel Dis 1997;3:230-235.
2. Simon GL, Gorbach SL: Intestinal flora in health and disease. Gastroenterology 1984;86:174-193.
3. Duchman R, Kaiser I, Hermann E, Mayet W, Ewe K, Meyer zum Buschenfelde KH: Tolerance exists towards resident intestinal flora but is broken in active inflammatory bowel disease (IBD). Clin Exp Immunol 1995;102:448-455.
4. Duchmann R, May E, Heike M, Knolle P, Neurath M, Meyer zum Buschenfelde KH: T cell specificity and cross-reactivity towards enterobacteria, Bacteroides, Bifidobacterium and antigens from resident intestinal flora in humans. Gut 1999;44:812-818.
5. Rutgeerts P, Goboes K, Peeters M, Hiele M, Penninckx F, Aerts R, Kerremans R, Vantrappen G: Effect of faecal stream diversion on recurrence of Crohn's disease in the neoterminal ileum. Lancet 1991;338:771-774.
6. D'Haens GR, Goboes K, Peeters M, Penninckx F, Rutgeerts P: Early lesions of recurrent Crohn's disease caused by infusion of intestinal contents in excluded ileum. Gastroenterology 1998;114:262-267.
7. Duchmann R, Schmitt E, Knolle P, Meyer zum Buschenfelde KH, Neurath M: Tolerance towards resident intestinal flora in mice is abrogated in experimental colitis and restored by treatment with interleukin-10 or antibodies to interleukin-12. Eur J Immunol 1996;26:934-938.
8. Sanderson JD, Moss MT, Tizard ML, Hermon-Taylor J: Mycobacterium paratuberculosis found in Crohn's disease DNA in Crohn's disease tissue. Gut 1992;33:890-896.
9. Darfeuille-Michaud A, Neut C, Barnich N, Lederman E, Di Martino P, Desreumaux P, Gambiez L, Joly B, Cortot A, Colombel JF: Presence of adherent Escherichia coli strains in ileal mucosa of patients with Crohn's disease. Gastroenterology 1998;115:1405-1413.
10. Sartor RB, Rath HC, Sellon RK: Microbial factors in chronic intestinal inflammation. Curr Opin Gastoenterol 1996;12:327-333.
11. Rhodes JM: Unifying hypothesis for inflammatory bowel disease and associated colon cancer: Sticking the pieces together with sugar. Lancet 1996;347:40-44.
12. Bamba T, Matsuda H, Endo M, Fujiyama Y: The pathogenetic role of Bacteroides vulgatus in patients with ulcerative colitis. J Gastroenterol 1995;30:45-47.
13. Nataro JP, Kaper JB: Diarrheagenic Escherichia coli. Clin Microbiol Rev 1998;11:142-201.
14. Walmsey RS, Anthony A, Sim R, Pounder RE, Wakefield AJ: Absence of Escherichia coli, Listeria monocytogenes and Klebsiella pneumoniae antigens within inflammatory bowel disease tissues. J Clin Pathol 1988;51:657-661.
15. Kallinowski F, Wassmer A, Hofmann MA, Harmsen D, Heesemann J, Karch H, Herfarth C, Buhr HJ: Frequency of enteropathogenic bacteria in surgically treated chronic inflammatory bowel disease. Hepatogastroenterology 1998;45:1552-1558.
16. Burke DA, Axon ATR: Ulcerative colitis and Escherichia coli with adhesive properties. J Clin Pathol 1987;40:782-786.
17. Burke DA, Axon ATR: Adhesive Escherichia coli in inflammatory bowel disease and infective diarrhea. BMJ 1988;297:102-104.
18. Schultsz C, Moussa M, van Ketel H, Tytgat GN, Dankert J: Frequency of pathogenic and enteroadherent Escherichia coli in patients with inflammatory bowel disease and controls. J Clin Pathol 1997;50:573-579.
19. von Wulffen H, Russmann H, Karch H, Karch H, Meyer T, Bitzan M, Kohrt TC, Aleksic S: Verocytoxin-producing Escherichia coli O2:H5 isolated from patients with ulcerative colitis. Lancet 1989;i:1449-1450.
20. Schultsz C, van den Berg FM, ten Kate FW, Tytgat GN, Dankert J: The intestinal mucus layer from patients with inflammatory bowel disease harbours numbers of bacteria compared with controls. Gastroenterology 1999;117:1089-1097.
21. Cummings JH: Short chain fatty acids in the human colon. Gut 1981;22:763-779.
22. Roedinger WEW: The colonic epithelium in ulcerative colitis: An energy deficient disease? Lancet 1980;ii:712-715.
23. Pitcher MC, Beatty ER, Cummings JH: The contribution of sulphate reducing bacteria and 5-aminosalicylic acid to faecal sulphide in patients with ulcerative colitis. Gut 2000;46:64-72.
24. Pitcher MCL, Cummings JH: Hydrogen sulphide: A bacterial toxin in ulcerative colitis? Gut 1996;39:1-4.
25. Marcus R, Watt J: Ulcerative colitis in laboratory animals induced by pepsin inhibitors. Gastroenterology 1974;67:473-483.
26. Pitcher MCL, Beatty ER, Cummings JH: Salicylates inhibit bacterial sulphide production within the colonic lumen in ulcerative colitis. Gut 1995;37:A15.
27. Dickinson RJ, O'Connor HJ, Pinder I, Hamilton I, Johnston D, Axon AT: Double-blind controlled trial of oral vancomycin as adjunctive treatment in acute exacerbations of idiopathic colitis. Gut 1985;26:1380-1384.
28. Chapman RW, Selby WS, Jewell DP: Controlled trial of intravenous metronidazole as adjunct to corticosteroids in severe ulcerative colitis. Gut 1986;27:1210-1212.
29. Burke DA, Axon ATR, Clayden SA, Dixon MF, Johnston D, Lacey RW: The efficacy of tobramycin in the treatment of ulcerative colitis. Aliment Pharmacol Ther 1990;4:123-129.
30. Mantzaris GJ, Hatzis A, Kontogiannis P, Triadaphyllou G: Intravenous tobramycin and metronidazole as an adjunct to corticosteroids in acute, severe ulcerative colitis. Am J Gastroenterol 1994;89:43-46.
31. Mantzaris GJ, Archavlis E, Christoforidis P, Kourtessas D, Amberiadis P, Florakis N, Petraki K, Spiliadi C, Triantafyllou G: A prospective randomised controlled trial of oral ciprofloxacin in acute ulcerative colitis. Am J Gastroenterol 1997;92:454-456.
32. Turunen UM, Farkkila MA, Hakala K, Seppala K, Sivonen A, Ogren M, Vuoristo M, Valtonen VV, Miettinen TA: Long-term treatment of ulcerative colitis with ciprofloxacin: A prospective, double-blind, placebo-controlled study. Gastroenterology 1998;115:1072-1078.
33. Casellas F, Borruel N, Papo M, Guarner F, Antolin M, Videla S, Malagelada JR: Anti-inflammatory effects of enterically coated amoxicillin-clavulanic acid in ulcerative colitis. Inflamm Bowel Dis 1998;4:1-5.
34. Blichfeldt P, Blomhoff JP, Myhre E, Gjone E: Metronidazole in Crohn's disease. A double-blind cross-over clinical trial. Scand J Gastroenterol 1978;13:123-127.
35. Ursing B, Alm T, Barany F, Bergelin I, Ganrot-Norlin K, Hoevels J, Huitfeldt B, Jarnerot G, Krause U, Krook A, Lindstrom B, Nordle O, Rosen A: A comparative study of metronidazole and sulfasalazine for active Crohn's disease: The cooperative Crohn's disease study in Sweden. II. Result. Gastroenterology 1982;83:550-562.
36. Ambrose NS, Allan RN, Keighley MR, Burdon DW, Youngs D, Lennard-Jones JE: Antibiotic therapy for treatment in relapse of intestinal Crohn's disease. A prospective randomized study. Dis Colon Rectum 1985;28:81-85.
37. Sutherland LR, Singleton T, Sessions T, Hanauer S, Krawitt E, Rankin G, Summers R, Mekhjian H, Greenberg N, Kelly M: Double-blind, placebo-controlled trial of metronidazole in Crohn's disease. Gut 1991;32:1071-1075.
38. Prantera C, Zannoni F, Scribano ML, Berto E, Andreoli A, Kohn A, Luzzi C: An antibiotic regimen for the treatment of active Crohn's disease: A randomized controlled clinical trial of metronidazole plus ciprofloxacin. Am J Gastroenterol 1996;91:328-332.
39. Colombel JF, Lemann M, Cassagnou M, Bouhnik Y, Duclols B, Dupas JL, Notteghem B, Mary JY: A controlled trial comparing ciprofloxacin with mesalazine for the treatment of active Crohn's disease. Am J Gastroenterol 1999;94:674-678.
40. Arnold GL, Beaves MR, Prydun VO, Mook WJ: Preliminary study of ciprofloxacin in active Crohn's disease. Inflamm Bowel Dis 2002;8:10-15.
41. Steinhart AH, Feagan BG, Wong CJ, Vandervoort M, Mikolainins S, Croitoru K, Seidmand E, Leddin DJ, Bitton A, Drouin E, Cohen A, Greemberg GR: Combined budesonide and antibiotic therapy for active Crohn's disease: A randomized controlled trial. Gastroenterology 2002;123:33-40.
42. Borgaonkar MR, MacIntosh DG, Fardy JM: A meta-analysis of antimycobacterial therapy for Crohn's disease. Am J Gastroenterol 2000;95:725-729.
43. Rutgeerts P, Hiele M, Geboes K, Peeters M, Penninckx F, Aerts R, Kerremans R: Controlled trial of metronidazole treatment for prevention of Crohn's recurrence after ileal resection. Gastroenterology 1995;108:1617-1621.
44. Rutgeerts P, D'Haens G, Baert F, et al: Nitroimidazol antibiotics are efficacious for prophylaxis of postoperative recurrence of Crohn's disease: A placebo controlled trial. Gastroenterology 1999;116:A808.
45. Gillis JC, Brogden RN: Rifaximin. A review of its antibacterial activity, pharmacokinetic properties and therapeutic potential in conditions mediated by gastrointestinal bacteria. Drugs 1995;49:467-484.
46. Pinto A, Borrutto G, Deall'Anna A, Turco L, Ferrieri A: An open, uncontrolled trial of oral rifaximin, a non-absorbable antibiotic, in inflammatory bowel disease refractory to conventional therapy. Eur J Clin Res 1997;9:217-224.
47. Gionchetti P, Rizzello F, Ferrieri A, Venturi A, Brignola C, Ferretti M, Peruzzo S, Miglioli M, Campieri M: Rifaximin in patients with moderate or severe ulcerative colitis refractory to steroid-treatment: A double-blind, placebo-controlled trial. Dig Dis Sci 1999;44:1220-1221.
48. Lukas M, Konecny M, Zboril V: Rifaximin in patients with mild to moderate activity of ulcerative colitis: An open label study. Gastroenterology 2002;122(suppl 1):A434.
49. Guslandi M, Giollo P, Testoni PA: Corticosteroid-sparing effect of rifaximin, a nonabsorbable oral antibiotic in active ulcerative colitis: Preliminary clinical experience. Curr Ther Res 2004;65:292-296.
50. Gionchetti P, Rizzello F, Venturi A, Ugolini F, Rossi M, Brigidi P, Johansson R, Ferrieri A, Poggioli G, Campieri M: Antibiotic combination therapy in patients with chronic, treatment-resistant pouchitis. Aliment Pharmacol Ther 1999;13:713-718.
51. Campieri M, Rizzello F, Venturi A, Poggioli G, Ugolini F, Helwig U, Amadini C, Romboli E, Gionchetti P: Combination of antibiotic and probiotic treatment is efficacious in prophylaxis of post-operative recurrence of Crohn's disease: A randomized controlled study versus mesalazine. Gastroenterology 2000;118(suppl 1):A781.
52. Shafran I, Dondelinger PJ, Johnson LK, et al: Efficacy and tolerability of rifaximin, a nonabsorbed, gut-selective, oral antibiotic in the treatment of active Crohn's disease: Results of an open-label study. Am J Gastroenterol 2003; 98(9 suppl):S250.